In this episode of LifeSci Talks, Mark Wade, Global Practice Leader at TransPerfect Life Sciences, sits down with Alice Biggane, Outcomes Innovation and Research Lead at Pfizer UK, to discuss how various PRO measures inform and impact reimbursement decisions for HTA driven markets. Together they unpack what data sources and methods exist for the quantification and understanding of HRQoL for cost-effectiveness decision making and the complex interplay between the need to reduce burden and increase transparency through standardization, while maintaining the crucial and nuanced balance of different stakeholder requirements. Tune in to learn how leading organizations are working to build more inclusive, efficient, and patient-focused clinical trials, and accelerating patient-access to new health technologies.
In this episode of TransPerfect LifeSci Talks, Mark Wade, Global Practice Leader at TransPerfect Life Sciences sits down with Tom Willgoss, Patient-Centered Outcomes Research...
In this episode of LifeSci Talks, Mark Wade, Global Practice Leader at TransPerfect Life Sciences, sits down with Stacey Higgins, Associate Director, COA &...
Mark Wade interviews Paul O'Donohoe, Senior Director of Product for eCOA and COA at Medidata. They delve into the challenges and opportunities of adopting...
